Physician profile
Annette Yung Kwon
NPI 1417009630
$13,226.41
in general payments reported to CMS, 2019-2025
30 companies · $3,730 in 2025
The $3,730 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $506 · 2021: $1,128 · 2022: $1,897 · 2023: $2,367 · 2024: $2,167 · 2025: $3,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,065 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,065.29 |
| Education | $198.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,770.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,003.54 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $1,835.02 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $726.25 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $628.19 | 2019-2025 | |
| Celltrion USA INC. | $401.13 | 2023-2025 | Vegzelma, Yuflyma |
| Lilly USA, LLC | $380.80 | 2024-2025 | Omvoh |
| Genzyme Corporation | $296.51 | 2023-2025 | |
| Braintree Laboratories, INC. | $273.32 | 2019-2025 | Suflave, Sutab |
| Gilead Sciences, INC. | $267.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.48 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $253.17 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $151.92 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $138.69 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $137.05 | 2019-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $137.02 | 2019 | |
| Nestle Healthcare Nutrition INC. | $82.60 | 2023 | |
| Phathom Pharmaceuticals, INC. | $66.96 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $65.48 | 2023-2024 | Idacio |
| Intercept Pharmaceuticals, INC. | $61.28 | 2020 | |
| Daiichi Sankyo INC. | $48.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.78 | 2023-2024 | Cyltezo |
| Medtronic, INC. | $36.79 | 2022 | |
| Ironwood Pharmaceuticals, INC | $29.82 | 2023-2024 | Linzess |
| Celgene Corporation | $25.38 | 2022 | |
| Ardelyx, INC. | $24.16 | 2025 | Ibsrela |
| Novo Nordisk INC | $20.47 | 2025 | Wegovy |
| Qol Medical, LLC | $20.35 | 2023 | Sucraid |
| W. L. Gore & Associates, INC. | $19.30 | 2020 | |
| Allergan, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.